Tenderwize
Wróć do wyszukiwania

Open house drug discount agreements

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline May 14, 2027 · 262 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge gem. § 130a (8c) SGB V ab 01.08.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

58/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

58 / 100

Złożoność

62 / 100

Czynniki ryzyka

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 3 lots
  • Duration until Jul 2027
  • Non-exclusive rebate agreements under Section 130a(8c) SGB V for oncology parenteral preparations made from finished medicinal products.
  • Active substances listed: bevacizumab (L01FG01), eribulin (L01XX41), rituximab (L01FA01), trastuzumab (L01FD01).
Pokaż pełne podsumowanie

Open-house pharmaceutical rebate agreement notice for three German regional lots (North Rhine-Westphalia, Hamburg, Schleswig-Holstein) covering oncology parenteral preparations made from finished medicinal products. The arrangement is non-exclusive, identical for all interested eligible pharmaceutical companies, with no award competition and no negotiated terms. Contract start is earliest 2025-08-01, duration up to 24 months, and the latest contract conclusion date is 2027-05-21. Submission is by email plus signed originals; electronic submission is otherwise marked not allowed in the notice metadata, so the submission mechanics should be checked carefully.

Ryzyka

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products and must remain so for the full contract term.
  • The company must have its registered seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Zamawiający

Lokalizacja

Dortmund, DEU

Identyfikator

DE124159739

Działalność

Health

Części (3)

LOT-0001

North Rhine-Westphalia region

Regional open-house rebate agreement for North Rhine-Westphalia. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 14, 2027

LOT-0002

Hamburg region

Regional open-house rebate agreement for Hamburg. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 14, 2027

LOT-0003

Schleswig-Holstein region

Regional open-house rebate agreement for Schleswig-Holstein. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 14, 2027

Szczegóły zamówienia

Data publikacji
25 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
338688-2025

Dokumenty (1)

Podobne przetargi